← Leaderboards
Anne Marie Quinn
Montana Molecular, Llc
$2,441,945
Attributed
$4,999,951
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $855.9K · FY2011–23$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,999,951 · 6
By mechanism
R44$4,458,769 · 4
R43$541,182 · 2
Top collaborators
- Thomas E Hughes13 shared
- Gregory David Gillispie1 shared
Others in their field
Top investigators on “Drug Discovery”
- David Heimbrook · Leidos Biomedical Research, Inc.$369,513,553
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ralph Parchment · Leidos Biomedical Research, Inc.$137,717,670
- Daniel Ernest Ford · Johns Hopkins University$137,014,543
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
Research focus
Drug DiscoveryMeasurementFluorescenceCellsSignal TransductionScreeningReaderBasePharmaceutical PreparationsSensorMolecularProteinsSiteBiosensorSignal PathwayResponseG Protein-Coupled Receptor SignalingGtp-Binding ProteinsPrototypeAgonistBiologicalPathway InteractionsCyclic AmpDrug Targeting
Grant awards (13)
Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery$300,000
R44 · FY2023 · AI · contact PI
An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder$315,386
R44 · FY2022 · DA · contact PI
Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery$300,000
R44 · FY2022 · AI · contact PI
An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder$482,109
R44 · FY2021 · DA · contact PI
A robust assay for detecting agonist bias in living cells.$600,181
R44 · FY2020 · GM · contact PI
A robust assay for detecting agonist bias in living cells.$634,836
R44 · FY2019 · GM · contact PI
An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder$221,097
R44 · FY2019 · DA · contact PI
Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue$210,309
R44 · FY2018 · NS · contact PI
Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue$227,000
R44 · FY2017 · NS · contact PI
A robust assay for detecting agonist bias in living cells.$193,000
R43 · FY2017 · GM · contact PI
Fast and Accurate Tools for Measuring Fluorescence in Living Cells$582,394
R44 · FY2015 · NS · contact PI
Fast and Accurate Tools for Measuring Fluorescence in Living Cells$585,457
R44 · FY2014 · NS · contact PI
Fast and Accurate Tools for Measuring Fluorescence in Living Cells$348,182
R43 · FY2011 · MH · contact PI